



Divi's Laboratories Limited

Date.20th May 2013

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051
Fax Nos.022 – 2659 8237 / 38

(by Fax, email & Courier)

Dear Sir,

Sub: Audited financial results for the year ended 31st March 2013
Ref: Clause 41 of Listing Agreement - Stock code: DIVISLAB
###


Pursuant to Clause 41 of the Listing Agreement, please find enclosed Audited Financial results along with consolidated financials for the year ended 31st March 2013.

Financial results were approved and taken on record by the Board of Directors of the Company at their meeting held on Monday, 20th May 2013. Further, Board of Directors has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended 31st March 2013.

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary
Encl: a/a

“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off : Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016. INDIA

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVIS LABORATORIES LIMITED
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2013

(Rs. in Lakhs)


Particulars	STANDALONE						CONSOLIDATED					
	Quarter ended			Year Ended			Quarter ended			Year Ended		
	31.03.2013 (Audited)	31.12.2012 (Unaudited)	31.03.2012 (Unaudited)	31.03.2013 (Audited)	31.03.2012 (Audited)		31.03.2013 (Audited)	31.12.2012 (Unaudited)	31.03.2012 (Unaudited)	31.03.2013 (Audited)	31.03.2012 (Audited)	
1	Income from operations	64961	53333	70796	212395	183949	65583	52953	71804	213990	185843	
	(a) Net Sales/Income from operations (Net of Excise Duty)											
	(b) Other Operating Income	167	103	346	494	544	167	104	347	494	544	
	Total Income from operations (net)	65128	53436	71142	212889	184493	65750	53057	72151	214484	186387	
2	Expenses											
	a. Cost of materials consumed	23317	26085	23771	89790	77177	23374	26182	23721	90063	77105	
	b. Purchases of stock-in-trade	0	9	10	9	10	13	17	0	30	0	
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	2091	(3972)	7271	(10033)	(1066)	2487	(5054)	7268	(10230)	(941)	
	d. Employee benefits expense	5386	4551	4393	19120	14516	5551	4717	4524	19772	15085	
	e. Depreciation and amortization expense	2027	2036	1663	7690	6203	2028	2037	1664	7695	6208	
	f. Other Expenses	9096	8532	7093	31828	24369	9306	9017	7636	33333	26098	
	Total expenses	41917	37241	44201	138404	121209	42759	36916	44813	140663	123555	
3	Profit from operations before other Income, finance costs & exceptional Items (1-2)	23211	16195	26941	74485	63284	22991	16141	27338	73821	62832	
4	Other Income	759	2232	437	4851	6576	760	1846	102	4481	5605	
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	23970	18427	27378	79336	69860	23751	17987	27440	78302	68437	
6	Finance Costs	62	44	242	178	374	62	44	242	178	374	
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	23908	18383	27136	79158	69486	23689	17943	27198	78124	68063	



[Handwritten Signature]

2	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
		69222100 100%	69222100 100%	69222100 100%	69222100 100%	69222100 100%	69222100 100%	69222100 100%	69222100 100%	69222100 100%
		52.15%	52.15%	52.15%	52.15%	52.15%	52.15%	52.15%	52.15%	52.15%

Particulars	Quarter ended 31.03.2013
B	
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	Nil




[Handwritten signature]

Statement of Assets and Liabilities:

(Rs. in lakhs)

	Particulars	STANDALONE		CONSOLIDATED	
		As At		As At	
		31.03.2013	31.03.2012	31.03.2013	31.03.2012
A	EQUITY AND LIABILITIES				
1	Shareholders' Funds				
a)	Share Capital	2655	2655	2655	2655
b)	Reserves and Surplus	252673	214825	247405	210498
c)	Money received against share warrants	0	0	0	0
	Sub-total – Shareholders' funds	255328	217480	250060	213153
2	Share application money pending allotment	0	0	0	0
3	Minority interest	0	0	0	0
4	Non-current liabilities				
a)	Long-term borrowings	210	256	210	256
b)	Deferred tax liabilities (net)	8655	6729	7922	6089
c)	Other long-term liabilities	0	625	0	625
d)	Long-term provisions	239	165	239	165
	Sub-total – Non-current liabilities	9104	7775	8371	7135
5	Current Liabilities				
a)	Short-term borrowings	3051	5020	3051	5020
b)	Trade payables	15831	15731	16044	15954
c)	Other current liabilities	12935	13470	13008	13583
d)	Short-term provisions	23342	20821	23342	20821
	Sub-total – Current liabilities	55159	55042	55445	55378
	TOTAL - EQUITY AND LIABILITIES	319591	280297	313876	275666
B	ASSETS				
1	Non-current assets				
a)	Fixed assets	121191	92018	121213	92040
b)	Goodwill on consolidation	0	0	0	0
c)	Non-current investments	282	282	0	0
d)	Deferred tax assets (net)	0	0	0	0
e)	Long-term loans and advances	10727	12469	6252	8138



2	f) Other non-current assets		0	393		0	393
	Sub-total - Non-current assets		132200	105162		127465	100571
Current assets	a) Current investments		40781	47704		40781	47704
	b) Inventories		80595	65097		83569	67896
	c) Trade receivables		55890	53397		51200	49508
	d) Cash and cash equivalents		3468	2182		4089	3094
	e) Short-term loans and advances		5989	6403		6104	6541
	f) Other current assets		668	352		668	352
	Sub-total - Current assets		187391	175135		186411	175095
TOTAL - ASSETS			319591	280297		313876	275666

NOTES:


1. The above audited results for the quarter and year ended 31st March 2013, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 20th May, 2013.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. The consolidated results include the audited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe A.G.
4. While there was a forex gain for the year, there was a forex loss during the current quarter as given below:

	Quarter ended	Year Ended	Quarter ended	Year Ended
Stand-alone	31-03-2013	31-03-2013	Consolidated	31-03-2013
Forex gain/(loss)	(975.10)	1516.40	(777.78)	1145.21

Forex gain has been included in Other Income and forex loss has been included in Other Expenses

5. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year's classification.
6. The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to March 31, 2013 and the unaudited published year-to-date figures up to December 31, 2012, being the date of the end of the third quarter of the financial year which were subjected to limited review.
7. The Board of Directors of the company has recommended a dividend of Rs. 15/- per equity share of Rs.2 each (i.e., 750%), subject to approval of members.

Place: Hyderabad
Date: 20-05-2013

for Divis Laboratories Limited

Dr. Murak K. Divi
Chairman & Managing Director

DIVI'S LABORATORIES LIMITED

Divi Towers, Dharam Karan Road

Hyderabad 500 016

Phone: 23786400 email: kishore@divislaboratories.com

PRESS RELEASE dated 20TH May, 2013

Divi's Labs earns a consolidated Total Income of Rs.2145 crores in FY13.

Consolidated for the year

Divi's Laboratories has earned a consolidated total income of Rs.2145 crores for the financial year 2012-13 as against a total income of Rs.1864 crores during the last year, reflecting a growth of 15%.

PBT for the current year came to Rs. 781 crores as against a PBT of Rs.681 crores for the previous year.

Tax for the year is provided at Rs.179 crores as against a tax provision of Rs.147 crores for the previous year.

PAT for the year is Rs. 602 crores as against a PAT of Rs.533 crores for the last year.

Consolidated for the 4th quarter

For the current quarter of the year, the company earned a PAT of Rs.181 crores on a total income of Rs.658 crores.

Standalone

On a standalone basis, the company's earnings are as given below:

Particulars	For the Quarter		For the year	
	Current	Previous	Current	Previous
Total Income	651	711	2129	1845



PBT	239	271	792	695
PAT	182	215	611	546

Operations

The Board has declared a dividend of Rs.15 per share i.e., 750% subject to approval of members.

Due to the continuing severe power shortage in the State of Andhra Pradesh, the company had to rely on purchased power at higher cost.

Particulars of forex gain/(loss) for the period are given below:

	Standalone		Consolidated	
	Quarter ended 31-03-13	Year Ended 31-03-13	Quarter ended 31-03-13	Year Ended 31-03-13
Forex gain/(loss)	(975.10)	1516.40	(777.78)	1145.21

While forex gain has been included in Other Income, forex loss has been included in Other Expenses.

Exports constituted 90% of sales and about 76% to advanced markets in North America and Europe.

During the year, addition to Fixed Assets amounted to Rs.248 crores. In addition, an amount of Rs.303 crores is carried forward as Capital WIP for the Capital Works under execution.

During the year Unit-II facility was successfully inspected by TGA, Australia (GMP), USFDA for Nutraceutical facility, USFDA for API site (pre-approval and cGMP), Slovenian Medicines Agency (EU GMP inspection for 7 APIs).

